|
**Overview**: **Allergy Regional East Profile****Introduction**: The Allergy Regional East Profile is a diagnostic tool designed to conduct screening for regional allergens in East India using serum samples. Associated with allergic disorders like rhinitis and asthma, these conditions present with sneezing, wheezing, and severe complications if untreated, particularly in individuals with regional environmental or dietary exposures. Per the 2023 American Academy of Allergy, Asthma & Immunology guidelines, the test employs allergology with immunoassay technology, delivering detailed allergen identification over 1-2 days with high sensitivity and specificity, making it a valuable tool for allergy screening in clinical settings. This diagnostic falls under allergy screening and targets individuals in East India with allergic symptoms, addressing the challenge of accurate allergen classification to guide avoidance or treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Reg East Pfl.**FDA Status**: FDA approved, CLIA certified for allergology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by various allergy labs, this test advanced regional allergy diagnostics by focusing on East Indian allergens.**Purpose**: The test screens for 14 allergens including total IgE and grass pollen to guide allergy assessment, assess immune response, and inform treatment and prevention strategies.**Test Parameters**: 1. Total IgE, 2. Grass Pollen (Bermuda), 3. Tree Pollen (Eucalyptus), 4. Weed Pollen (Ragweed), 5. Dust Mite (D. pteronyssinus), 6. Dust Mite (D. farinae), 7. Cat Dander, 8. Dog Dander, 9. Cockroach, 10. Mold (Alternaria), 11. House Dust, 12. Rice, 13. Banana, 14. Mustard.**Pretest Condition**: No fasting required; patients should avoid antihistamines and report sneezing, wheezing, or recent allergen exposure.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on sneezing, wheezing, prior allergic reactions, or family history of allergies, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated allergies including asthma, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antihistamine use can affect results. Correlation with clinical evaluation or skin testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible regional allergic sensitivities, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early sensitization stages.**Specialist Consultation**: General practitioners or specialists in allergology or pulmonology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Skin prick test, specific IgE levels, or pulmonary function test for confirmation.**Test Limitations**: The test may produce false negatives in early sensitization or false positives in cross-reactive conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: AAAAI Guidelines 2023, Journal of Allergy and Clinical Immunology 2024, Allergology 2025. |
